Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) is a developer of prescription transdermal pharmaceutical products, with a primary focus on its AVERSA abuse-deterrent transdermal technology and its lead product candidate, an abuse-deterrent fentanyl patch. The Nutriband news stream highlights how the company is advancing this technology platform, interacting with regulators, and managing its corporate structure to support product development.
Readers of the Nutriband news page can follow regulatory and clinical development updates, including the company’s reported meetings with the U.S. Food and Drug Administration on the Chemistry, Manufacturing, and Controls plans and the 505(b)(2) NDA pathway for AVERSA Fentanyl. News items also cover Nutriband’s summaries of FDA feedback on in vitro studies to characterize abuse-deterrent properties and its intention to move toward an IND filing in support of a Human Abuse Potential clinical study.
The company’s releases also describe intellectual property developments, such as a provisional patent application to enhance AVERSA technology and U.S. patent actions related to abuse and misuse deterrent transdermal systems, alongside references to a broad patent portfolio covering AVERSA in multiple countries. Corporate and capital markets news includes announcements of a preferred stock dividend tied to future FDA approval of AVERSA Fentanyl, the sale of a majority stake in subsidiary Pocono Pharmaceutical to EarthVision Bio, and Nutriband’s inclusion in Russell indexes.
Additional coverage includes partnership and collaboration news, such as agreements with Kindeva Drug Delivery for product development, Brand Institute for commercial brand name creation, and a non-binding Letter of Intent with the Qvanta Group to explore advanced technology support for abuse-deterrent pharmaceutical innovation. Investors and observers can use this page to review how Nutriband presents its progress on AVERSA Fentanyl, its stance on issues like illicit versus prescription fentanyl, and its participation in investor conferences and public communications.
Nutriband (NASDAQ: NTRB / NTRBW) summarized key points from its Jan 24, 2026 annual shareholder meeting in Orlando. Highlights include board additions, AVERSA™ FENTANYL development progress, patent milestones, manufacturing scale-up, a Type C meeting with the US FDA, planned IND and HAL clinical trial work, ongoing Pocono Pharma sale activity, a FINRA complaint, and 2026 warrant expirations.
Notable specifics: exclusive development partnership with Kindeva, new patents in the US and Macao, collection of $30,000 in closing-extension penalties, and 91,0904 warrants expiring Oct 1, 2026 with $6.43 strike.
Nutriband (NASDAQ:NTRB / NTRBW) CEO Gareth Sheridan published a shareholder letter summarizing 2025 milestones and 2026 outlook. Key 2025 developments include a $5M sale for 90% of the Pocono subsidiary to EarthVision Bio, a 25% preferred stock dividend issued July 25, 2025 (convertible on FDA approval of AVERSA Fentanyl), and USPTO patent issuance No. 12,318,492 on June 3, 2025 covering abuse‑deterrent transdermal systems.
Other items: commercial manufacturing scale‑up completed in June 2025, a Type C meeting with FDA on CMC and pathway to a 505(b)(2) NDA, addition to four Russell indexes, and warrants from the 2021 IPO expiring Oct 1, 2026.
Nutriband (NASDAQ: NTRB / NTRBW) signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5.0 million. Shareholders will retain a 10% stake in EarthVision Bio after the transaction. The expected closing date is Dec 31, 2025. Nutriband said it will use sale proceeds to fund continued development of AVERSA Fentanyl, described as a potential abuse‑deterrent transdermal fentanyl patch. The company disclosed projected potential US annual sales for AVERSA Fentanyl of $80M–$200M.
EarthVision Bio is described as commercializing sustainable products developed by Dr. Gordon Moore and Dr. Hans Franke; Nutriband will no longer hold majority control of Pocono Pharmaceutical after closing.
Nutriband (NASDAQ: NTRB / NTRBW) announced a non-binding Letter of Intent dated Dec 18, 2025 to explore advanced technology collaboration with Qvanta Group of Companies.
The LOI contemplates joint evaluation of quantum‑ready AI simulation, secure high‑performance computing, and cybersecurity/data‑integrity frameworks to support Nutriband’s abuse‑deterrent pharmaceutical research and product development. The parties will emphasize regulatory compliance and data protection. The LOI is non‑binding and expressly states there is no assurance a definitive agreement or transaction will occur.
Nutriband (NASDAQ:NTRB) announced development of AVERSA™ FENTANYL, an abuse‑deterrent transdermal fentanyl system combining Nutriband’s AVERSA™ technology with Kindeva’s FDA‑approved fentanyl patch.
The company positioned this program in response to the U.S. Executive Order designating illicit fentanyl and core precursors as weapons of mass destruction (Dec 15, 2025), while stressing that FDA‑approved prescription fentanyl remains medically necessary. Nutriband cites ongoing abuse/accidental exposure risks and projects peak annual U.S. sales of $80M–$200M for AVERSA™ FENTANYL. The AVERSA™ IP portfolio includes patents issued in 46 countries.
Nutriband (NASDAQ: NTRB / NTRBW) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21 — Noble Capital Markets' 21st Emerging Growth Equity Conference in Boca Raton, FL on December 3, 2025 at 9:30 AM ET.
Interested investors may register at a discounted rate using code NTRBNOBLECON. A high-definition webcast will be posted the following day on nobleconference.com and channelchek.com and archived for 90 days.
Nutriband develops transdermal pharmaceuticals; its lead program is an abuse-deterrent fentanyl patch using AVERSA™ technology.
Nutriband (NASDAQ:NTRB) received final meeting minutes from a Sept 18, 2025 virtual face-to-face meeting with the US FDA regarding its lead product AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system. FDA confirmed the regulatory pathway as a 505(b)(2) NDA and provided CMC feedback on registration batch plans, manufacturing process validation, product specifications, stability testing, and planned Category 1 in vitro manipulation/extraction studies. Nutriband is incorporating FDA guidance as it advances toward an IND filing to support a Human Abuse Potential (HAP) clinical study. The company partners with Kindeva and cites a peak US sales potential of $80M–$200M. Nutriband holds patents in 46 countries.
Nutriband (NASDAQ: NTRB / NTRBW) announced that co-founder Gareth Sheridan has returned as CEO effective October 27, 2025. From August 10 to October 27, co-founder and chairman Serguei Melnik covered CEO duties.
Mr. Sheridan will lead the company through the remainder of 2025 toward a targeted NDA filing in 2026 for AVERSA FENTANYL, an abuse‑deterrent transdermal fentanyl patch. Management cites a Health Advances market analysis estimating peak U.S. sales of $80M–$200M. The AVERSA technology is protected by patents in 46 countries.
Nutriband (NASDAQ:NTRB / NTRBW) announced on October 10, 2025 that its 4P Therapeutics subsidiary signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, the development-named AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system using AVERSA™ technology.
Brand Institute will provide naming and identity services and regulatory support via its Drug Safety Institute, leveraging prior experience with drug-name approvals and regulatory naming guidance.
Nutriband (NASDAQ:NTRB) filed a provisional patent application with the USPTO on October 8, 2025 to strengthen intellectual property covering its AVERSA™ transdermal abuse deterrent technology. The filing targets improved aversive formulations and coating application methods designed to enhance deterrence for patches containing opioids and stimulants.
The company notes AVERSA is already covered by issued patents in 46 countries and says conversion to a non‑provisional application and a subsequent patent grant could extend U.S. patent protection (statutory term starts from the non‑provisional filing date).
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
